South Korea
· Delayed Price · Currency is KRW BioNote Statistics
Total Valuation
BioNote has a market cap or net worth of KRW 472.01 billion. The enterprise value is 59.24 billion.
| Market Cap | 472.01B |
| Enterprise Value | 59.24B |
Important Dates
The next estimated earnings date is Thursday, November 14, 2024.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
BioNote has 102.06 million shares outstanding. The number of shares has increased by 4.14% in one year.
| Shares Outstanding | 102.06M |
| Shares Change (YoY) | +4.14% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 61.10% |
| Owned by Institutions (%) | 0.18% |
| Float | 11.74M |
Valuation Ratios
The trailing PE ratio is 5.79.
| PE Ratio | 5.79 |
| Forward PE | n/a |
| PS Ratio | 4.96 |
| PB Ratio | 0.30 |
| P/FCF Ratio | 10.99 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 2.63, with an EV/FCF ratio of 1.38.
| EV / Earnings | 0.73 |
| EV / Sales | 0.62 |
| EV / EBITDA | 2.63 |
| EV / EBIT | 4.11 |
| EV / FCF | 1.38 |
Financial Position
The company has a current ratio of 25.93, with a Debt / Equity ratio of 0.00.
| Current Ratio | 25.93 |
| Quick Ratio | 24.41 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.17 |
| Debt / FCF | 0.09 |
| Interest Coverage | 21.31 |
Financial Efficiency
Return on equity (ROE) is 5.31% and return on invested capital (ROIC) is 0.58%.
| Return on Equity (ROE) | 5.31% |
| Return on Assets (ROA) | 0.56% |
| Return on Capital (ROIC) | 0.58% |
| Revenue Per Employee | 319.06M |
| Profits Per Employee | 274.00M |
| Employee Count | 298 |
| Asset Turnover | 0.06 |
| Inventory Turnover | 1.73 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +5.98% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +5.98% |
| 50-Day Moving Average | 4,639.80 |
| 200-Day Moving Average | 4,342.23 |
| Relative Strength Index (RSI) | 50.45 |
| Average Volume (20 Days) | 134,145 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioNote had revenue of KRW 95.08 billion and earned 81.65 billion in profits. Earnings per share was 798.94.
| Revenue | 95.08B |
| Gross Profit | 46.88B |
| Operating Income | 14.41B |
| Pretax Income | 25.78B |
| Net Income | 81.65B |
| EBITDA | 22.52B |
| EBIT | 14.41B |
| Earnings Per Share (EPS) | 798.94 |
Balance Sheet
The company has 416.70 billion in cash and 3.93 billion in debt, giving a net cash position of 412.77 billion or 4,044.54 per share.
| Cash & Cash Equivalents | 416.70B |
| Total Debt | 3.93B |
| Net Cash | 412.77B |
| Net Cash Per Share | 4,044.54 |
| Equity (Book Value) | 1.59T |
| Book Value Per Share | 15,543.68 |
| Working Capital | 449.05B |
Cash Flow
In the last 12 months, operating cash flow was 50.55 billion and capital expenditures -7.62 billion, giving a free cash flow of 42.93 billion.
| Operating Cash Flow | 50.55B |
| Capital Expenditures | -7.62B |
| Free Cash Flow | 42.93B |
| FCF Per Share | 420.65 |
Margins
Gross margin is 49.30%, with operating and profit margins of 15.16% and 85.88%.
| Gross Margin | 49.30% |
| Operating Margin | 15.16% |
| Pretax Margin | 27.11% |
| Profit Margin | 85.88% |
| EBITDA Margin | 23.68% |
| EBIT Margin | 15.16% |
| FCF Margin | 45.15% |
Dividends & Yields
BioNote does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | 25.00% |
| Buyback Yield | -4.14% |
| Shareholder Yield | -4.14% |
| Earnings Yield | 17.27% |
| FCF Yield | 9.10% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioNote has an Altman Z-Score of 7.12.
| Altman Z-Score | 7.12 |
| Piotroski F-Score | n/a |